Adage Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-920,000
| Closed | -$95.2M | – | 928 |
|
|
2022
Q4 | $95.2M | Buy |
920,000
+70,000
| +8% | +$7.24M | 0.23% | 109 |
|
|
2022
Q3 | $72.1M | Sell |
850,000
-525,000
| -38% | -$44.5M | 0.18% | 134 |
|
|
2022
Q2 | $114M | Sell |
1,375,000
-100,000
| -7% | -$8.29M | 0.26% | 79 |
|
|
2022
Q1 | $114M | Sell |
1,475,000
-390,000
| -21% | -$30.1M | 0.22% | 99 |
|
|
2021
Q4 | $165M | Buy |
1,865,000
+1,470,498
| +373% | +$130M | 0.3% | 67 |
|
|
2021
Q3 | $30.5M | Buy |
+394,502
| New | +$30.5M | 0.06% | 329 |
|
|
2020
Q4 | – | Sell |
-484,000
| Closed | -$36.8M | – | 817 |
|
|
2020
Q3 | $36.8M | Sell |
484,000
-410,000
| -46% | -$31.2M | 0.09% | 232 |
|
|
2020
Q2 | $110M | Buy |
894,000
+559,124
| +167% | +$69M | 0.28% | 77 |
|
|
2020
Q1 | $28.3M | Buy |
+334,876
| New | +$28.3M | 0.08% | 253 |
|
|
2019
Q2 | – | Sell |
-84,000
| Closed | -$7.46M | – | 713 |
|
|
2019
Q1 | $7.46M | Buy |
+84,000
| New | +$7.46M | 0.02% | 566 |
|
|
2017
Q3 | – | Sell |
-673,000
| Closed | -$61.1M | – | 714 |
|
|
2017
Q2 | $61.1M | Hold |
673,000
| – | – | 0.15% | 191 |
|
|
2017
Q1 | $59.1M | Buy |
673,000
+3,000
| +0.4% | +$263K | 0.15% | 195 |
|
|
2016
Q4 | $55.5M | Buy |
670,000
+45,000
| +7% | +$3.73M | 0.15% | 186 |
|
|
2016
Q3 | $57.8M | Sell |
625,000
-375,000
| -38% | -$34.7M | 0.16% | 166 |
|
|
2016
Q2 | $77.8M | Sell |
1,000,000
-52,900
| -5% | -$4.12M | 0.21% | 131 |
|
|
2016
Q1 | $86.8M | Buy |
1,052,900
+800,000
| +316% | +$66M | 0.24% | 121 |
|
|
2015
Q4 | $26.5M | Sell |
252,900
-124,000
| -33% | -$13M | 0.07% | 316 |
|
|
2015
Q3 | $39.7M | Sell |
376,900
-50,000
| -12% | -$5.27M | 0.11% | 238 |
|
|
2015
Q2 | $58.4M | Buy |
426,900
+239,000
| +127% | +$32.7M | 0.15% | 200 |
|
|
2015
Q1 | $23.4M | Buy |
+187,900
| New | +$23.4M | 0.06% | 388 |
|